Economic evaluation of pooled solvent/detergent treated plasma versus single donor fresh-frozen plasma in patients receiving plasma transfusions in the United States

• Published in: Transfusion and apheresis science Vol. 51; no. 1; pp. 17 - 24
• Main Authors: Huisman, Eline L, de Silva, Shamika U, de Peuter, Maria A
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-08-2014
• Subjects: Adult; Blood Component Transfusion - economics; Cost-effectiveness analysis; Costs and Cost Analysis; Detergents; Female; Fresh-frozen plasma; Health technology assessment; Hematology, Oncology and Palliative Medicine; Humans; Male; Middle Aged; Models, Economic; Octaplas; Plasma; Solvents; Transfusion; United States; United States; Cost-effectiveness analysis; Transfusion; Fresh-frozen plasma; Octaplas; United States
• ISSN: 1473-0502; 1878-1683
• DOI: 10.1016/j.transci.2014.07.006

Abstract This study assessed the cost-effectiveness of Octaplas™ versus fresh frozen plasma (FFP) in patients receiving plasma transfusions in the United States (US). Acute and long-term complications of plasma transfusions were modelled in a decision tree followed by a Markov model, using a healthcare payer perspective. Over a lifetime time horizon, patients receiving Octaplas™ accumulate slightly more life years (0.00613 [95% uncertainty interval (95%UI): 0.00166–0.01561]) and quality-adjusted life years (QALY) (0.023 [95%UI: 0.012–0.044]) at lower cost compared with those treated with FFP. Octaplas™ demonstrated to be the dominant treatment option over FFP (95%UI: Dominant–US$ 15,764/QALY).